Company news

Longeveron Inc. news in 2023

Longeveron Inc.'s news releases, calls and decks from 2023, newest first.

View company

Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

December 20, 2023

Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease

December 19, 2023

Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer’s Disease With Lomecel-B™

December 5, 2023

Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update

November 9, 2023

Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023

November 2, 2023

Longeveron Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

October 12, 2023

Longeveron Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

October 11, 2023

Longeveron Announces Positive Top-Line Results for Lomecel-B™ in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer’s Disease

October 4, 2023

Longeveron Rights Offering Subscription Period Begins

August 21, 2023

Longeveron Rights Offering Declared Effective and Calendar Finalized

August 15, 2023

Longeveron Announces Pricing for Rights Offering and Expected Calendar

August 13, 2023

Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update

August 10, 2023

Longeveron Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome

August 10, 2023

Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions

August 7, 2023

Longeveron to Report Second Quarter 2023 Results and Provide Corporate Update on August 11, 2023

August 6, 2023

Longeveron Appoints Lisa Locklear as Chief Financial Officer

July 19, 2023

Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer

July 10, 2023

Longeveron Files Registration Statement for Rights Offering

June 26, 2023

Longeveron Welcomes Three New Prominent Board Members

June 12, 2023

Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 11, 2023

Longeveron Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome

May 8, 2023

Longeveron to Announce First Quarter 2023 Financial Results on May 12, 2023

May 7, 2023

Longeveron Announces First Patient Dosed in Phase 2 Clinical Trial of Lomecel-B™ for Aging-Related Frailty in Japan

April 18, 2023

Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

March 9, 2023

Longeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023

March 5, 2023

Longeveron Appoints Wa’el Hashad as Chief Executive Officer

February 27, 2023

Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal

January 18, 2023

Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones

January 5, 2023

Calls in 2023

Decks in 2023